DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Telcagepant is an investigational drug.
There have been 11 clinical trials for Telcagepant. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2007.
The most common disease conditions in clinical trials are Migraine Disorders, Heart Diseases, and Stroke. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Recent Clinical Trials for Telcagepant
|Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)||Merck Sharp & Dohme Corp.||Phase 2/Phase 3|
|Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)||Merck Sharp & Dohme Corp.||Phase 1|
|A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)||Merck Sharp & Dohme Corp.||Phase 2|